Literature DB >> 33749820

Expression of miRNA in obesity and insulin resistance: a review.

Paulina Estrella Ibarra1,2, Pablo García-Solís2, Juan Carlos Solís-Sáinz2, Andrés Cruz-Hernández3.   

Abstract

MicroRNAs (miRNAs) are part of the epigenetic mechanisms that regulate gene expression at a post-transcriptional level. This review describes some miRNAs whose expression is modified in obesity and that may be involved in the development of insulin resistance. The metabolic alterations associated with obesity are due to an adipose tissue dysfunction. miRNAs are a mechanism that regulates gene expression, one miRNA can regulate the expression up to a thousand genes, and at the same time one gene can be regulated by several miRNAs; moreover, miRNA expression is tissue specific. Obesity leads to a dysregulation of miRNA expression in adipose tissue, and changes in miRNA expression relate to changes in gene expression related to the development of insulin resistance. However, because miRNA can be exported to the extracellular medium through exosomes, proteins, and lipoproteins, miRNA can be found in extracellular fluids like blood, urine, saliva, and cerebrospinal fluid. Considering the above, miRNA have been proposed as biological markers of different diseases, and also as potential therapeutic targets.

Entities:  

Keywords:  adipose tissue; epigenetics; insulin resistance; microRNA; obesity

Year:  2021        PMID: 33749820     DOI: 10.5603/EP.a2021.0002

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  2 in total

Review 1.  Neuroendocrine microRNAs linked to energy homeostasis: future therapeutic potential.

Authors:  Kimberly W Y Mak; Aws F Mustafa; Denise D Belsham
Journal:  Pharmacol Rep       Date:  2022-09-09       Impact factor: 3.919

2.  MicroRNA loaded edible nanoparticles: an emerging personalized therapeutic approach for the treatment of obesity and metabolic disorders.

Authors:  F Campolo; G Catanzaro; M A Venneri; E Ferretti; Z M Besharat
Journal:  Theranostics       Date:  2022-03-05       Impact factor: 11.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.